Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L46 (MRPL46) is a nuclear-encoded protein that functions as a structural constituent of the 39S large subunit of the mitochondrial ribosome (mitoribosome)[1][2][4]. Its primary role is to contribute to the assembly and function of the mitoribosome, which synthesizes proteins within mitochondria that are crucial for mitochondrial respiratory chain complexes and cellular energy production[1][4][5][6]. MRPL46 participates in maintaining translation fidelity and proper mitoribosome assembly[9]. Mitochondrial ribosomal proteins such as MRPL46 exhibit unique non-redundant roles in diverse tissues, especially those with high energy demands[3][4]. Mutations or dysregulation of MRPL46 and other MRPs have been linked to various mitochondrial disorders and some cancers[2][3][4][11]. No known small molecule drugs or direct modulators target MRPL46, and it is not currently considered a therapeutic target but rather a critical housekeeping protein essential for mitochondrial protein synthesis and cellular metabolism[1][2][4][9][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L46 (MRPL46).